Back to Search
Start Over
The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation
- Source :
- Journal for Immunotherapy of Cancer, Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-14 (2019)
- Publication Year :
- 2019
- Publisher :
- BioMed Central, 2019.
-
Abstract
- Background The CTLA-4 blocking antibody ipilimumab has demonstrated substantial and durable effects in patients with melanoma. While CTLA-4 therapy, both as monotherapy and in combination with PD-1 targeting therapies, has great potential in many indications, the toxicities of the current treatment regimens may limit their use. Thus, there is a medical need for new CTLA-4 targeting therapies with improved benefit-risk profile. Methods ATOR-1015 is a human CTLA-4 x OX40 targeting IgG1 bispecific antibody generated by linking an optimized version of the Ig-like V-type domain of human CD86, a natural CTLA-4 ligand, to an agonistic OX40 antibody. In vitro evaluation of T-cell activation and T regulatory cell (Treg) depletion was performed using purified cells from healthy human donors or cell lines. In vivo anti-tumor responses were studied using human OX40 transgenic (knock-in) mice with established syngeneic tumors. Tumors and spleens from treated mice were analyzed for CD8+ T cell and Treg frequencies, T-cell activation markers and tumor localization using flow cytometry. Results ATOR-1015 induces T-cell activation and Treg depletion in vitro. Treatment with ATOR-1015 reduces tumor growth and improves survival in several syngeneic tumor models, including bladder, colon and pancreas cancer models. It is further demonstrated that ATOR-1015 induces tumor-specific and long-term immunological memory and enhances the response to PD-1 inhibition. Moreover, ATOR-1015 localizes to the tumor area where it reduces the frequency of Tregs and increases the number and activation of CD8+ T cells. Conclusions By targeting CTLA-4 and OX40 simultaneously, ATOR-1015 is directed to the tumor area where it induces enhanced immune activation, and thus has the potential to be a next generation CTLA-4 targeting therapy with improved clinical efficacy and reduced toxicity. ATOR-1015 is also expected to act synergistically with anti-PD-1/PD-L1 therapy. The pre-clinical data support clinical development of ATOR-1015, and a first-in-human trial has started (NCT03782467). Electronic supplementary material The online version of this article (10.1186/s40425-019-0570-8) contains supplementary material, which is available to authorized users.
- Subjects :
- 0301 basic medicine
Male
Cancer Research
T-Lymphocytes, Regulatory
Mice
0302 clinical medicine
Solid tumors
Antibodies, Bispecific
Immunology and Allergy
Medicine
OX40
CTLA-4 Antigen
Melanoma
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
medicine.anatomical_structure
Oncology
030220 oncology & carcinogenesis
Molecular Medicine
Female
medicine.drug
Research Article
Regulatory T cell
T cell
Immunology
Primary Cell Culture
Ipilimumab
Mice, Transgenic
CHO Cells
lcsh:RC254-282
Proof of Concept Study
03 medical and health sciences
Cricetulus
Cell Line, Tumor
Blocking antibody
Animals
Humans
Pharmacology
CD86
business.industry
Receptors, OX40
medicine.disease
Disease Models, Animal
030104 developmental biology
HEK293 Cells
Urinary Bladder Neoplasms
CTLA-4
Cancer research
Drug Screening Assays, Antitumor
business
CD8
Subjects
Details
- Language :
- English
- ISSN :
- 20511426
- Volume :
- 7
- Database :
- OpenAIRE
- Journal :
- Journal for Immunotherapy of Cancer
- Accession number :
- edsair.doi.dedup.....09cbba20b753513ce8ee3f014583fcfc